Ligand Pharmaceuticals Incorporated - Common Stock (LGND)

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its

Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

After Monday's panicked global sell-off, markets have calmed down.